MADRIGAL PHARMACEUTICALS, INC. Income Tax Examination, Penalties and Interest Expense
MADRIGAL PHARMACEUTICALS, INC. (MDGL) reported Income Tax Examination, Penalties and Interest Expense of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-19.
Financial Statements › Expense Statement › Interest Expense
us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense · last filed 2026-02-19
- MADRIGAL PHARMACEUTICALS, INC. income tax examination, penalties and interest expense for fiscal 2025 was $0.00.
- MADRIGAL PHARMACEUTICALS, INC. income tax examination, penalties and interest expense for fiscal 2024 was $0.00.
- MADRIGAL PHARMACEUTICALS, INC. income tax examination, penalties and interest expense for fiscal 2023 was $0.00.
- MADRIGAL PHARMACEUTICALS, INC. income tax examination, penalties and interest expense for fiscal 2022 was $0.00.
| Period end | Income Tax Examination, Penalties and Interest Expense 12 month |
|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-02-19 |
| 2024-12-31 | $0.00 10-K · filed 2025-02-26 |
| 2023-12-31 | $0.00 10-K · filed 2024-02-28 |
| 2022-12-31 | $0.00 10-K/A · filed 2023-03-03 |
| 2021-12-31 | $0.00 10-K · filed 2022-02-24 |
| 2020-12-31 | $0.00 10-K · filed 2021-02-25 |
| 2019-12-31 | $0.00 10-K · filed 2020-02-26 |
| 2018-12-31 | $0.00 10-K · filed 2019-02-27 |
| 2017-12-31 | $0.00 10-K · filed 2018-03-13 |
| 2016-12-31 | $0.00 10-K · filed 2017-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |